Evidence map›Paper›PMID 41214141›Full record

ArticleLeukemia2025

Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Michiyuki Maeda, Hideki Goto, Tomoyuki Endo, Takanori Teshima, Yibin Yang and 1 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Keito SutoDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID http://orcid.org/0000-0001-8212-5664
Norio TakeiInstitute for Animal Experimentation, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Keito YokoyamaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Masahiro ChibaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID http://orcid.org/0000-0003-2731-6091
Takashi IshioDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Michiyuki MaedaInstitute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Hideki GotoDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Tomoyuki EndoDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Takanori TeshimaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.ORCID http://orcid.org/0000-0002-0941-271X
Yibin YangCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9948-8696
Masao NakagawaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan. nakagawam@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-8602-6054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41214141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.